Double attack on blood cancer: stem cell transplant plus CAR-T shows promise

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior line of therapy. \*\[Note: LBCL includes: diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); diffuse large B-cell lymphoma transformed from follicular lymphoma (FL-DLBCL); grade 3b follicular lymphoma (FL); primary mediastinal large B-cell lymphoma (PMBCL); high-grade B-cell lymphoma with rearrangements of MYC and BCL-2 and/or BCL-6 (double-hit/triple-hit lymphoma, DHL/THL)\].\* 2. Age Restriction: Individuals must be 18 to 70 years old. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 4. Presence of at least one measurable target lesion. \*\[Note: A target lesion is defined as ≥1 lesion with a longest diameter (LD) \>1.5 cm and a longest perpendicular diameter (LPD) ≥1.0 cm, as assessed by computed tomography (CT) or magnetic resonance imaging (MRI).\]\* 5. Adequate organ function, defined as: * Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; * Creatinine clearance ≥30 mL/min; * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN). 6. Adequate hematopoietic function, defined as: * Platelet count ≥45 ×10⁹/L; * Hemoglobin ≥8.0 g/dL; * Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L. 7. Life expectancy ≥3 months. 8. For women of childbearing potential, a negative pregnancy test is required. Both male and female patients must agree to use effective contraception during treatment and for 1 year thereafter. 9. Willingness to provide written informed consent. Exclusion Criteria: 1. Prior allogeneic hematopoietic stem cell transplantation or CAR-T cell therapy. 2. Use of immunosuppressive agents or systemic corticosteroids (equivalent to \>10 mg prednisone daily) within 2 weeks prior to leukapheresis, or requirement for continued use after enrollment. 3. Active hepatitis B (HBsAg positive with detectable HBV DNA) or hepatitis C (anti-HCV positive with detectable HCV RNA) infection at screening. 4. Uncontrolled active infection requiring intravenous antimicrobial therapy. 5. History of other malignancies within 2 years prior to enrollment (except adequately treated basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ). 6. Significant comorbidities that may compromise study participation or patient safety, including: * Severe cardiovascular disease (NYHA Class III/IV heart failure, myocardial infarction within 6 months, unstable arrhythmias, or angina) * Severe pulmonary dysfunction (FEV1 or DLCO ≤50% predicted, or requiring supplemental oxygen) 7. HIV infection (positive serology with detectable viral load). 8. Pregnancy, lactation, or unwillingness to use effective contraception. 9. Any condition that in the investigator's judgment would preclude safe participation.